Orca Bio’s Orca-T FDA review extended to July 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Rusan unveils APOSAN 3ml multi-dose pen

The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks

Teva hits major biosimilar milestones with FDA nod and regulatory filings

The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia

Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy

The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract

Apollo Hospitals expands air ambulance services offerings

Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I

The approval covers pediatric patients without a matched sibling donor for stem cell transplant